US 11,786,553 B2
Chimeric cytokine receptors bearing a PD-1 ectodomain
Regina Junhui Lin, San Mateo, CA (US); Thomas John Van Blarcom, Oakland, CA (US); Siler Panowski, Berkeley, CA (US); and Barbra Johnson Sasu, San Francisco, CA (US)
Assigned to ALLOGENE THERAPEUCTICS, INC., South San Francisco, CA (US)
Filed by Allogene Therapeutics, Inc., South San Francisco, CA (US)
Filed on Feb. 28, 2020, as Appl. No. 16/804,545.
Claims priority of provisional application 62/980,737, filed on Feb. 24, 2020.
Claims priority of provisional application 62/894,659, filed on Aug. 30, 2019.
Claims priority of provisional application 62/812,799, filed on Mar. 1, 2019.
Prior Publication US 2020/0276238 A1, Sep. 3, 2020
Int. Cl. C07K 14/715 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 35/17 (2015.01); C12N 15/67 (2006.01); A61K 38/00 (2006.01)
CPC A61K 35/17 (2013.01) [C07K 14/7155 (2013.01); C07K 16/2818 (2013.01); C07K 16/30 (2013.01); C12N 15/67 (2013.01); A61K 38/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01)] 33 Claims
 
1. A PD-1 chimeric cytokine receptor comprising:
a. a PD-1 ectodomain or an antigen binding domain of an anti-PD-L1 or an anti-PD-L2 antibody;
b. a transmembrane domain;
c. a Janus Kinase (JAK)-binding domain; and
d. a recruiting domain comprising a STAT-recruiting domain from IL2Rb,
wherein the transmembrane domain and JAK-binding domain comprise SEQ ID NO: 40, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO: 27.